Movement Disorders

Oct. news includes an approved deep brain stimulation system for movement disorders & biomarkers that improve risk assessment in atrial fibrillation.

Our Sept. news includes a possible clinical marker and therapy target in Alzheimer disease and MS findings from an optical coherence tomography study.

Our August news includes a potential classification system for Alzheimer disease, new findings in a 3D model of TBI, and migraine treatments.

A study of 30 years indicates the projected increase in Parkinson disease could be underestimated and offers possible explanations.

Recent neurological studies outline a link between TBI and Parkinson disease, discuss neuroimaging to predict recovery, and warn against DIY tDCS.

Our July news includes the Alzheimer-diabetes link, increased rates of Parkinson, and guidelines for acute migraine treatment in the ED.

Nuplazid, which the FDA designated as a breakthrough therapy and granted priority review, could help approximately 50% of Parkinson patients.

Our May news includes memory replay disruption in Alzheimer disease, impulse control disorder in Parkinson disease, and return to play in TBI.

Technology that is efficient yet lacking side effects, personalized, and nonintrusive may be closer than we think for many of our neurology patients.

Researchers gather environmental data to better understand possible mechanisms of Parkinson disease development.

Our Feb. news & research include two new migraine drugs, the stroke-Parkinson link, and the potential of an anticancer drug to prevent Alzheimer.

Our Jan. news & research list includes the possible lingering effects of childhood concussion and the benefits of vitamin D for MS.

Compliance, an obstacle in depression treatment for all patients, can be especially difficult for patients with dementia.

Our Dec. news & research list includes groundbreaking research from AES 2015 as well as a few potential neurodegeneration biomarkers.

A groundbreaking discovery may lead to repair of neurodegenerative diseases such as Alzheimer and Parkinson.

The holidays can be an especially stressful time of year, so patients need to be aware of how stress influences neurological disease progression.

The discovery of a possible trigger for PD and Lewy body dementia could provide a new avenue for gene therapy in these neurological conditions.

Our Nov. news & research list includes 2 successful genetic Alzheimer treatments in mouse models and a potential drug for Parkinson disease psychosis.

A recent webinar summarized on-going efforts to halt Parkinson disease, including several phase III trials.

Dysregulated dopamine may not be the sole cause of impulse control problems in patients with Parkinson disease.

Dopamine may not be the only neurotransmitter affected in Parkinson disease.

A Johns Hopkins team is designing the STIMband, a non-invasive brain-stimulating device that may provide at-home Parkinson treatment.

Researchers test a compound that shows promise as a Parkinson treatment.

Studies of a kuru epidemic in a formerly cannibalistic tribe could lead to further understanding of other neurodegenerative diseases, such as Alzheimer and Parkinson.